Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yuming Wang

Yuming Wang

Southwest Hospital, China

Title: A randomly controlled study comparing efficacy among three combination therapies with different pegylated interferon alfa plus nucleot(s)ide analogues in NUCs-treated HBeAg-positive CHB patients

Biography

Biography: Yuming Wang

Abstract

Adding pegylated interferon alfa in HBeAg-positive CHB patients treated with long-term nucleot(s)ide analogues (NUCs) therapy has demonstrated obvious improvement in HBeAg seroconversion [1,2] and HBsAg loss or seroconversion.[3,4] Thus, it was reported to improve efficacy by adding PEG IFN α in NUC-treated patients.

Aim

This study was to compare response rates of three different pegylated interferon alfa combined with NUCs in NUC-treated HBeAg-positive patients.

Material and Methods

HBeAg-positive CHB patients that achieved HBsAg ≤1000IU/mL, HBeAg ≤5 S/COI and HBeAb ≤2 S/COI after a long-term NUCs treatment (≥2years), were randomized to receive combination therapies of PEG IFN α and NUCs for 24 weeks. Satisfactory response (virological and biochemical response, plus anti-HBe seroconversion) was defined as primary endpoint, ideal response (HBsAg loss) was defined as secondary endpoint. All patients with/without withdrawing drugs were keeping further followed up.

Results

Totally, 105 NUC-treated HBeAg-positive CHB patients with HBV markers fulfilling above-mentioned criteria were enrolled and randomized to receive 40kD PEG IFN-α-2a+NUCs combination therapy (180μg/week, Group A, n=38), 12kD PEG IFN-α-2b +NUCs combination therapy (80μg/week, Group B, n=35), or 40kD PEG IFN-α-2b +NUCs combination therapy (180μg/week, Group C, n=32). There were no significant differences in sex, age, HBV genotype and ALT level among the three groups (P>0.05). Satisfactory response rate in Group C (26.3%,10/38)was slightly higherthan in Group A (22.8%, 8/35, P=0.7320)and Group B (31.2%,  10/32, P=0.6489). 40kD PEG IFN-α-2b +NUCs combination therapy achieved significantly higher ideal response rates (18.8%, 6/32) than Group A (5.26%, 2/38, P=0.0773) and Group B (2.86%, 1/35,P=0.0336).(P<0.05).

Conclusion

In NUCs-treated HBeAg-positive CHB patients with low level of HBsAg and HBeAg/HBeAb, our result showed that ideal response rate in 40kD PEG IFN-α-2b +NUCs combination group was higher than in 40kD PEG IFN-α-2a +NUCs and 12kD PEG IFN-α-2b +NUCs combination therapies.

Table.  Responses in three groups after treatment for 24 weeks

response

Group A

40kD PEG IFN-α-2a+NUCs (n=38)

Group B

12kD PEG IFN α-2b+NUCs(n=35)

Group C

40kD PEG IFN-α-2b

+NUCs (n=32)

P value

Satisfactory response

10 (26.3%)

8 (22.8%)

10 (31.2%)

C vs. A

P=0.7320,C vs.

B P=0.6489

Ideal response

2 (5.26%)

1 (2.86%)

6 (18.8%)

C vs. A

P=0.0773, C

vs.B P=0.0336